These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23027415)

  • 1. 5-HT(2C) agonists as therapeutics for the treatment of schizophrenia.
    Rosenzweig-Lipson S; Comery TA; Marquis KL; Gross J; Dunlop J
    Handb Exp Pharmacol; 2012; (213):147-65. PubMed ID: 23027415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist.
    Dunlop J; Watts SW; Barrett JE; Coupet J; Harrison B; Mazandarani H; Nawoschik S; Pangalos MN; Ramamoorthy S; Schechter L; Smith D; Stack G; Zhang J; Zhang G; Rosenzweig-Lipson S
    J Pharmacol Exp Ther; 2011 Jun; 337(3):673-80. PubMed ID: 21402690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.
    Thomsen WJ; Grottick AJ; Menzaghi F; Reyes-Saldana H; Espitia S; Yuskin D; Whelan K; Martin M; Morgan M; Chen W; Al-Shamma H; Smith B; Chalmers D; Behan D
    J Pharmacol Exp Ther; 2008 May; 325(2):577-87. PubMed ID: 18252809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-HT2C receptor agonists as an innovative approach for psychiatric disorders.
    Rosenzweig-Lipson S; Dunlop J; Marquis KL
    Drug News Perspect; 2007 Nov; 20(9):565-71. PubMed ID: 18176661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutive activity of serotonin 2C receptors at G protein-independent signaling: modulation by RNA editing and antidepressants.
    Labasque M; Meffre J; Carrat G; Becamel C; Bockaert J; Marin P
    Mol Pharmacol; 2010 Nov; 78(5):818-26. PubMed ID: 20699324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity.
    Berg KA; Cropper JD; Niswender CM; Sanders-Bush E; Emeson RB; Clarke WP
    Br J Pharmacol; 2001 Sep; 134(2):386-92. PubMed ID: 11564657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy.
    Niswender CM; Herrick-Davis K; Dilley GE; Meltzer HY; Overholser JC; Stockmeier CA; Emeson RB; Sanders-Bush E
    Neuropsychopharmacology; 2001 May; 24(5):478-91. PubMed ID: 11282248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA editing of the 5-HT(2C) receptor is reduced in schizophrenia.
    Sodhi MS; Burnet PW; Makoff AJ; Kerwin RW; Harrison PJ
    Mol Psychiatry; 2001 Jul; 6(4):373-9. PubMed ID: 11443520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin 5-HT(2C) receptor homodimerization is not regulated by agonist or inverse agonist treatment.
    Herrick-Davis K; Grinde E; Weaver BA
    Eur J Pharmacol; 2007 Jul; 568(1-3):45-53. PubMed ID: 17507008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity.
    Siuciak JA; Chapin DS; McCarthy SA; Guanowsky V; Brown J; Chiang P; Marala R; Patterson T; Seymour PA; Swick A; Iredale PA
    Neuropharmacology; 2007 Feb; 52(2):279-90. PubMed ID: 16949622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lorcaserin for the treatment of obesity.
    Redman LM; Ravussin E
    Drugs Today (Barc); 2010 Dec; 46(12):901-10. PubMed ID: 21589947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic administration of 5-HT(2C) receptor agonists attenuates muscular hyperalgesia in reserpine-induced myalgia model.
    Ogino S; Nagakura Y; Tsukamoto M; Watabiki T; Ozawa T; Oe T; Shimizu Y; Ito H
    Pharmacol Biochem Behav; 2013 Jul; 108():8-15. PubMed ID: 23603031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiallodynic effects of intrathecally administered 5-HT(2C) receptor agonists in rats with nerve injury.
    Obata H; Saito S; Sakurazawa S; Sasaki M; Usui T; Goto F
    Pain; 2004 Mar; 108(1-2):163-9. PubMed ID: 15109520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).
    Yang Y; An S; Liu Y; Guo XX; Gao L; Wei JF; Xu TR
    Expert Opin Ther Pat; 2016; 26(1):89-106. PubMed ID: 26609882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-HT2 ligands in the treatment of anxiety and depression.
    Quesseveur G; Nguyen HT; Gardier AM; Guiard BP
    Expert Opin Investig Drugs; 2012 Nov; 21(11):1701-25. PubMed ID: 22917059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics.
    Sumiyoshi T; Bubenikova-Valesova V; Horacek J; Bert B
    Adv Ther; 2008 Oct; 25(10):1037-56. PubMed ID: 18839076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Serotonin 2C Receptor Agonist Lorcaserin Attenuates Intracranial Self-Stimulation and Blocks the Reward-Enhancing Effects of Nicotine.
    Zeeb FD; Higgins GA; Fletcher PJ
    ACS Chem Neurosci; 2015 Jul; 6(7):1231-40. PubMed ID: 25781911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of serotonin-2C receptor G-protein coupling by RNA editing.
    Burns CM; Chu H; Rueter SM; Hutchinson LK; Canton H; Sanders-Bush E; Emeson RB
    Nature; 1997 May; 387(6630):303-8. PubMed ID: 9153397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications.
    Dunlop J; Marquis KL; Lim HK; Leung L; Kao J; Cheesman C; Rosenzweig-Lipson S
    CNS Drug Rev; 2006; 12(3-4):167-77. PubMed ID: 17227285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin2C ligands exhibiting full negative and positive intrinsic activity elicit purposeless oral movements in rats: distinct effects of agonists and inverse agonists in a rat model of Parkinson's disease.
    Navailles S; Lagière M; Roumegous A; Polito M; Boujema MB; Cador M; Dunlop J; Chesselet MF; Millan MJ; De Deurwaerdère P
    Int J Neuropsychopharmacol; 2013 Apr; 16(3):593-606. PubMed ID: 22717119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.